CGEMCullinan Therapeutics Inc.Signing up patients
CLN-049 in Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)
Relapsed/Refractory Acute Myeloid Leukemia (AML) · Myelodysplastic Syndrome (MDS) · TP53-mutated MDS and AML
0Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 1/2
- Patients
- 275 (planned)
- Started
- Nov 18, 2021
- Main results expected
- Dec 30, 2029
- Fully finished
- Dec 30, 2029
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Number of treatment emergent events (TEAEs)
Measured over: 28 days
Cmax of CLN-049
Measured over: Up to 13 weeks
Ctrough of CLN-049
Measured over: 28 Days
Tmax of CLN-049
Measured over: 28 Days
T1/2 of CLN-049
Measured over: Up to 28 days
Efficacy of CLN-049
Measured over: Up to 13 weeks
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT05143996 · record last updated 2026-10-28 · checked 2026-11-09 15:47 UTC